Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Protein phosphatase 2A (PP2A) complexes function as tumor suppressors by inhibiting the activity of several critical oncogenic signaling pathways. Consequently, inhibition of the PP2A phosphatase activity is one of many prerequisites for the transformation of normal human cells into cancerous cells. However, mechanisms for PP2A inactivation in human cancers are poorly understood. The aberrant expression of cancerous inhibitor of protein phosphatase 2A (CIP2A), a recently identified endogenous PP2A inhibitor in malignant cells, is one such mechanism. Various independent studies have validated CIP2A's role in promoting tumor growth and resistance to apoptosis and senescence-inducing therapies. Notably, high CIP2A expression predicts poor patient prognosis in several human cancer types. Among the oncogenic proteins dephosphorylated by PP2A, the MYC oncoprotein, which is phosphorylated at serine 62, has surfaced as a marker for the oncogenic activity of CIP2A. The positive-feedback loop between CIP2A and MYC augments the activity of MYC in cancer cells. In addition, CIP2A promotes the phosphorylation and activity of additional oncoproteins, including E2F1 and AKT. However, CIP2A is not essential for normal mouse growth and development. These findings indicate that CIP2A is a novel anticancer target based on PP2A reactivation and inhibition of the oncogenic activity of its downstream effectors. The potential approaches and feasibility of targeting CIP2A are discussed here. Cancer Res; 73(22); 6548–53. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“its depletion results in inactivation of many oncogenic PP2A targets (e.g., MYC, E2F1, Akt) [6]”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [6]
In the citing paper
“This establishes the reactivation of PP2A as an attractive novel approach in cancer therapy [2,6]”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [6]
In the citing paper
“CIP2A has been shown to promote phosphorylation and activity of both of these critical PP2A targets [6,9,10,12,16]”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [6]
In the citing paper
“PP2A complex components are mutated at a relatively low frequency in most types of human cancer”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [6]
In the citing paper
“Binding of CIP2A to PP2A via specific B subunits imposes an interesting possible explanation for observations that CIP2A only regulates a fairly restricted number of phosphoproteins [6,13] among thousands of potential target proteins regulated by different PP2A complexes [24,26].”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [6]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791 · cited 2×
“At the posttranslational level, MYC is regulated by phosphorylation at several phosphorylation sites, and several kinases, such as ERK, JNK2, CK2, and Cdk1, have been demonstrated to phosphorylate MYC on serine 62, the PP2A target residue (21, 26).”
BackgroundTabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698 · cited 1×
“A number of RNAi-based preclinical and clinical trials are ongoing, and a recent study showed several durable responses and an example of a cured patient following an RNAi trial therapy in patients with liver metastases (29).”
BackgroundCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 4×
“In contrast to testicular progenitors and various tumor cells, CIP2A expression is relatively low in most normal human and mouse tissues (4, 19), which may also explain the viability of CIP2A mutant mice.”
BackgroundInfluentialSelf-citationProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400 · cited 6×
“The first indication that PP1 and PP2A complexes have tumor suppressor activities was obtained from studies using the serine/threonine phosphatase inhibitor okadaic acid, which is a potent inhibitor of PP2A but also inhibits PP1 at higher concentrations (2, 3).”
BackgroundResultInfluentialMultiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 10×
“The first indication that PP1 and PP2A complexes have tumor suppressor activities was obtained from studies using the serine/threonine phosphatase inhibitor okadaic acid, which is a potent inhibitor of PP2A but also inhibits PP1 at higher concentrations (2, 3).”
BackgroundResultInfluentialSelf-citationThe Ins and Outs of MYC Regulation by Posttranslational Mechanisms
Vervoorts, J., Lüscher-Firzlaff, J., & Lüscher, B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600017200 · Cited by 260 · cited 3×
“At the posttranslational level, MYC is regulated by phosphorylation at several phosphorylation sites, and several kinases, such as ERK, JNK2, CK2, and Cdk1, have been demonstrated to phosphorylate MYC on serine 62, the PP2A target residue (21, 26).”
BackgroundInterfacial inhibitors: targeting macromolecular complexes
Pommier, Y., & Marchand, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3404 · Cited by 259
CIP2A Is Associated with Human Breast Cancer Aggressivity
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3283 · Cited by 221 · cited 2×
“Furthermore, despite the convincing effects of CIP2A inhibition on xenograft tumor growth (4, 9, 11, 12, 15), we lack genetic in vivomodels to test the therapeutic potential of acute CIP2A inhibition for cancer therapy.”
BackgroundSelf-citationHoo, L. S., Zhang, J. Y., & Chan, E. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205625 · Cited by 201
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185 · cited 5×
“Furthermore, CIP2A and MYC are coexpressed in hepatocellular, colon, andNSCLC tissue samples (9, 12, 13).”
BackgroundInfluentialSelf-citation
Cited by
Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression
Guo, B., Wu, S., Zhu, X., Zhang, L., Deng, J., Li, F., Wang, Y., Zhang, S., Wu, R., Lu, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019102190 · Cited by 243
“CIP2A (cancerous inhibitor of PP2A cancer inhibitory factor) is an oncogene that promotes tumor progression through inhibiting PP2A and promoting AKT, MYC, and E2F1 activities (Junttila et al , 2007; Khanna et al , 2013; Janghorban et al , 2014).”
Chemical probes and drug leads from advances in synthetic planning and methodology
Gerry, C. J., & Schreiber, S. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.53 · Cited by 230
O’Connor, C. M., Perl, A., Leonard, D., Sangodkar, J., & Narla, G. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.008 · Cited by 190
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 148
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143
Metadata
- Authors
- Khanna, A., Pimanda, J. E., & Westermarck, J.
- Affiliations
- Åbo Akademi University (FI)
- Venue
- Cancer Research
- Published
- 2013-11-14
- Volume
- 73
- Issue
- 22
- Pages
- 6548-6553
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2158492983
- Cited by
- 154
- References
- 32
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 4 · 2023: 9 · 2022: 8 · 2021: 17 · 2020: 12 · 2019: 9 · 2018: 16 · 2017: 18 · 2016: 14 · 2015: 25 · 2014: 9 · 2013: 1
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- CIP2A, protein phosphatase 2A, PP2A inhibition, MYC phosphorylation, E2F1, Akt, tumor suppressor inactivation, apoptosis resistance, senescence resistance, cancer prognosis, anticancer drug targets, positive feedback loop
- MeSH terms
- Animals, Autoantigens, Cell Transformation, Neoplastic, Humans, Membrane Proteins, Neoplasms, Oncogene Proteins, Gene Expression Regulation, Neoplastic, Intracellular Signaling Peptides and Proteins, Mice, Protein Phosphatase 2, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-1994
- The paper
- Khanna, A., Pimanda, J. E., & Westermarck, J. (2013). Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-1994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.